- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00113529
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
25. srpna 2011 aktualizováno: Pfizer
A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Gefitinib (Iressa) In Patients With Metastatic Renal Cell Carcinoma
To assess the maximum tolerated dose and overall safety and tolerability of sunitinib [SU011248] administered in combination with gefitinib (Iressa) for the treatment of patients with metastatic renal cell carcinoma (Phase 1).
To assess antitumor activity of the combination of gefitinib and sunitinib (Phase 2).
Přehled studie
Typ studie
Intervenční
Zápis (Aktuální)
42
Fáze
- Fáze 2
- Fáze 1
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- Pfizer Investigational Site
-
-
New York
-
New York, New York, Spojené státy, 10021
- Pfizer Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19111-2497
- Pfizer Investigational Site
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
18 let a starší (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion Criteria:
- Histologically confirmed renal cell carcinoma with metastases
- Evidence of unidimensionally measurable disease
- Failure of 1 prior immunotherapy or no prior systemic therapy for metastatic RCC
Exclusion Criteria:
- RCC without any clear (conventional) cell component
- History of or known brain metastases
- Uncontrolled hypertension or other significant cardiac events within the 12 months prior to study entry
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Sunitinib + Gefitinib
Phase 1 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib; 50 mg Sunitinib + 250 mg Gefitinib Phase 2 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib |
Until disease progression or unacceptable toxicity.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Number of Subjects With Overall Confirmed Objective Disease Response According to the Response Evaluation Criteria in Solid Tumors (RECIST)
Časové okno: From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter
|
Objective disease response = subjects with confirmed complete response (CR) or partial response (PR) according to RECIST.
A CR was defined as the disappearance of all target lesions.
A PR was defined as a ≥ 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
|
From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Time to Tumor Response (TTR)
Časové okno: From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter
|
TTR was defined as the time from date of the first dose of study medication to first documentation of objective tumor response (CR or PR).
For subjects proceeding from PR to CR, the onset of PR was taken as the onset of response.
If lesion assessment data included more than 1 date, the first date was used.
TTR was calculated as (first event date minus first dose date +1)/7.
TTR was calculated based on the subgroup of subjects with a baseline disease assessment, who had the correct histological cancer type, and had a confirmed objective tumor response.
Kaplan-Meier method was used.
|
From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter
|
Duration of Response (DR)
Časové okno: From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter or death due to cancer
|
DR was defined as the time from start of the first documentation of objective tumor response to the first documentation of objective tumor progression or death due to any cause, whichever occurred first.
If tumor progression data included more than 1 date, the first date was used.
DR was calculated as (the end date for DR minus first CR or PR that was subsequently confirmed +1)/7.
DR was calculated for the subgroup of subjects with an objective tumor response (CR or PR).
|
From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter or death due to cancer
|
Time to Tumor Progression (TTP)
Časové okno: From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter
|
TTP was defined as the time from the date of first dose of study medication to first documentation of objective tumor progression.
If tumor progression data included more than 1 date, the first date was used.
TTP (in weeks) was calculated as (first event date minus first dose date +1)/7.
Kaplan-Meier method was used.
|
From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter
|
Overall Survival (OS)
Časové okno: From start of study treatment until death
|
OS was defined as the time from date of the first dose of study medication to date of death due to any cause.
OS (in weeks) is calculated as (date of death minus first dose date +1)/7.
For subjects not expiring, their survival times were censored at the last date of known contact they were known to be alive.
Subjects lacking data beyond the day of first dose had their survival times censored at 1 day.
Kaplan-Meier method was used.
|
From start of study treatment until death
|
Progression-Free Survival (PFS)
Časové okno: From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter or death
|
PFS was defined as the time from the date of first dose of study medication to the date of first documentation of tumor progression or death due to any cause, whichever occurred first.
If tumor progression data included more than 1 date, the first date was used.
PFS (in weeks) was calculated as (first event date minus first dose date +1)/7.
Kaplan-Meier method was used.
|
From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter or death
|
Probability of Survival at One Year
Časové okno: From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter up until 1 year
|
Survival rate was defined as the percentage of subjects alive at 1 year after the date of first administration of study medication.
Survival rate was estimated using the Kaplan-Meier method.
|
From start of treatment until Day 28 of Cycles 1 to 4, Day 28 of even cycles thereafter up until 1 year
|
VEGF (Vascular Endothelial Growth Factor) Concentration at Baseline
Časové okno: Baseline (Cycle 1, Day 1)
|
Concentration of VEGF at baseline.
|
Baseline (Cycle 1, Day 1)
|
VEGF Ratio to Baseline at Each Time Point
Časové okno: Baseline to Cycle 3, Day 28 inclusive
|
VEGF concentration at each time point divided by VEGF concentration at baseline (ratio to baseline).
|
Baseline to Cycle 3, Day 28 inclusive
|
VEGF-C Concentration at Baseline
Časové okno: Baseline (Cycle 1, Day 1)
|
Concentration of VEGF-C at baseline.
|
Baseline (Cycle 1, Day 1)
|
VEGF-C Ratio to Baseline at Each Time Point
Časové okno: Baseline to Cycle 3, Day 28 inclusive
|
VEGF-C concentration at each time point divided by VEGF-C concentration at baseline (ratio to baseline).
|
Baseline to Cycle 3, Day 28 inclusive
|
Soluble VEGF Receptor 2 (sVEGFR2) Concentration at Baseline
Časové okno: Baseline (Cycle 1, Day 1)
|
Concentration of sVEGFR2 at baseline.
|
Baseline (Cycle 1, Day 1)
|
sVEGFR2 Ratio to Baseline at Each Time Point
Časové okno: Baseline to Cycle 3, Day 28 inclusive
|
sVEGFR2 concentration at each time point divided by sVEGFR2 concentration at baseline (ratio to baseline).
|
Baseline to Cycle 3, Day 28 inclusive
|
Soluble VEGF Receptor 3 (sVEGFR3) Concentration at Baseline
Časové okno: Baseline (Cycle 1, Day 1)
|
Concentration of sVEGFR3 at baseline.
|
Baseline (Cycle 1, Day 1)
|
sVEGFR3 Ratio to Baseline at Each Time Point
Časové okno: Baseline to Cycle 3, Day 28 inclusive
|
sVEGFR3 concentration at each time point divided by sVEGFR3 concentration at baseline (ratio to baseline).
|
Baseline to Cycle 3, Day 28 inclusive
|
Change From Baseline in VEGF by Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] Versus PD)
Časové okno: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change = median VEGF level at each specified time point for subjects with tumor response (CR or PR or [SD > = 6 weeks] versus PD) minus median VEGF level at Baseline.
A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).
|
Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change From Baseline in VEGFC by Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] Versus PD)
Časové okno: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change = median VEGFC level at each specified time point for subjects with tumor response (CR or PR or [SD > = 6 weeks] versus PD) minus median VEGFC level at Baseline.
A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).
|
Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change From Baseline in VEGFR2 by Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] Versus PD)
Časové okno: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change = median VEGFR2 level at each specified time point for subjects with tumor response (CR or PR or [SD > = 6 weeks] versus PD) minus median VEGFR2 level at Baseline.
A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).
|
Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change From Baseline in VEGFR3 by Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] Versus PD)
Časové okno: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change = median VEGFR3 level at each specified time point for subjects with tumor response (CR or PR or [SD > = 6 weeks] versus PD) minus median VEGFR3 level at Baseline.
A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).
|
Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change From Baseline in VEGF by Time Point Stratified by PFS >= Median and PFS < Median
Časové okno: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change = median VEGF level at each specified time point for subjects with tumor response PFS >= Median or PFS < Median minus median VEGF level at Baseline.
A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).
|
Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change From Baseline in VEGFC by Time Point Stratified by PFS >= Median and PFS < Median
Časové okno: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change = median VEGFC level at each specified time point for subjects with tumor response PFS >= Median or PFS < Median minus median VEGFC level at Baseline.
A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).
|
Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change From Baseline in VEGFR2 by Time Point Stratified by PFS >= Median and PFS < Median
Časové okno: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change = median VEGFR2 level at each specified time point for subjects with tumor response PFS >= Median or PFS < Median minus median VEGFR2 level at Baseline.
A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).
|
Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change From Baseline in VEGFR3 by Time Point Stratified by PFS >= Median and PFS < Median
Časové okno: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change = median VEGFR3 level at each specified time point for subjects with tumor response PFS >= Median or PFS < Median minus median VEGFR3 level at Baseline.
A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).
|
Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change From Baseline in VEGF by Time Point Stratified by TTP >= Median and TTP < Median
Časové okno: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change = median VEGF level at each specified time point for subjects with tumor response TTP >= Median and TTP < Median minus median VEGF level at Baseline.
A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).
|
Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change From Baseline in VEGFC by Time Point Stratified by TTP >= Median and TTP < Median
Časové okno: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change = median VEGFC level at each specified time point for subjects with tumor response TTP >= Median and TTP < Median minus median VEGFC level at Baseline.
A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).
|
Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change From Baseline in VEGFR2 by Time Point Stratified by TTP >= Median and TTP < Median
Časové okno: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change = median VEGFR2 level at each specified time point for subjects with tumor response TTP >= Median and TTP < Median minus median VEGFR2 level at Baseline.
A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).
|
Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change From Baseline in VEGFR3 by Time Point Stratified by TTP >= Median and TTP < Median
Časové okno: Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Change = median VEGFR3 level at each specified time point for subjects with tumor response TTP >= Median and TTP < Median minus median VEGFR3 level at Baseline.
A measure of dispersion is not included because the Wilcoxon rank sum test is a non-parametric test that makes no assumptions about the distribution of the data (eg, normality).
|
Baseline (Cycle 1, Day 1) to Cycle 3, Day 28 inclusive
|
Trough Plasma Concentrations (Ctrough) of Sunitinib
Časové okno: prior to dosing on Cycle 1 (Days 1, 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28)
|
prior to dosing on Cycle 1 (Days 1, 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28)
|
|
Ctrough of SU-012662 (Sunitinib's Metabolite)
Časové okno: prior to dosing on Cycle 1 (Days 1, 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28)
|
prior to dosing on Cycle 1 (Days 1, 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28)
|
|
Ctrough of Gefitinib
Časové okno: prior to dosing on Cycle 1 (Days 1, 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28)
|
prior to dosing on Cycle 1 (Days 1, 28), Cycle 2 (Days 1, 28), Cycle 3 (Days 1, 28)
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Publikace a užitečné odkazy
Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia
1. října 2004
Primární dokončení (Aktuální)
1. září 2007
Dokončení studie (Aktuální)
1. října 2008
Termíny zápisu do studia
První předloženo
8. června 2005
První předloženo, které splnilo kritéria kontroly kvality
8. června 2005
První zveřejněno (Odhad)
9. června 2005
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
29. srpna 2011
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
25. srpna 2011
Naposledy ověřeno
1. srpna 2011
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Novotvary podle histologického typu
- Novotvary
- Urologické novotvary
- Urogenitální novotvary
- Novotvary podle místa
- Onemocnění ledvin
- Urologická onemocnění
- Adenokarcinom
- Novotvary, žlázové a epiteliální
- Novotvary ledvin
- Karcinom, renální buňka
- Karcinom
- Fyziologické účinky léků
- Molekulární mechanismy farmakologického působení
- Inhibitory enzymů
- Antineoplastická činidla
- Inhibitory angiogeneze
- Činidla modulující angiogenezi
- Růstové látky
- Inhibitory růstu
- Inhibitory proteinkinázy
- Sunitinib
- Gefitinib
Další identifikační čísla studie
- A6181038
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Karcinom, renální buňka
-
Northwestern UniversityNational Cancer Institute (NCI)UkončenoRakovina ledvin | Hereditary Clear Cell Renal Cell CarcinomaSpojené státy
-
Guru SonpavdePfizer; Hoosier Cancer Research NetworkStaženoRakovina ledvin | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney CarcinomaSpojené státy
-
Mirati Therapeutics Inc.DokončenoClear-cell Renal Cell CarcinomaSpojené státy
-
RenJi HospitalShanghai Zhongshan Hospital; Ruijin HospitalNáborClear Cell Renal Cell Carcinoma、Rezistence na imunoterapiiČína
-
Debiopharm International SANáborDuktální adenokarcinom slinivky břišní (PDAC) | Kolorektální karcinom (CRC) | Clear Cell Renal Cell Cancer (ccRCC)Francie, Austrálie
-
Peloton Therapeutics, Inc.Aktivní, ne náborRakovina ledvin | Renální buněčný karcinom | Rakovina ledvin | Renální buněčný karcinom (RCC) | Metastatický karcinom ledvinových buněk | Ledviny | Clear Cell Renal Cell Carcinoma (ccRCC) | Recidivující renální buněčný karcinom | Renální buněčná rakovina, recidivujícíSpojené státy
-
Regeneron PharmaceuticalsZatím nenabírámeMelanom | Pokročilé pevné nádory | Clear-cell Renal-Carcinoma (ccRCC)
-
Regeneron PharmaceuticalsNáborMetastatický karcinom prostaty odolný proti kastraci (mCRPC) | Clear Cell Renal Cell Carcinoma (ccRCC)Spojené státy
-
Kura Oncology, Inc.Mirati Therapeutics Inc.NáborNemalobuněčný karcinom plic (NSCLC) | Duktální adenokarcinom slinivky břišní (PDAC) | Kolorektální karcinom (CRC) | Clear Cell Renal Cell Carcinoma (ccRCC) | Solidní nádory se změnami HRASSpojené státy
-
Calithera Biosciences, IncUkončenoMelanom | Nemalobuněčný karcinom plic (NSCLC) | Clear Cell Renal Cell Carcinoma (ccRCC)Spojené státy
Klinické studie na Gefitinib + Sunitinib
-
Sun Yat-sen UniversityNeznámýGastrointestinální rakovinyČína
-
Sun Yat-sen UniversityNeznámý
-
Qilu Pharmaceutical Co., Ltd.NeznámýNemalobuněčný karcinom plicČína
-
Samsung Medical CenterDokončenoNovotvary žaludkuKorejská republika
-
AstraZenecaDokončenoNovotvary, dlaždicové buňkySpojené státy, Česká republika, Polsko, Německo, Belgie, Tchaj-wan, Indie, Srbsko
-
Kunming Medical UniversityUkončenoNemalobuněčný karcinom plicČína
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Dokončeno
-
Duke UniversityNational Cancer Institute (NCI)DokončenoNádory mozku a centrálního nervového systémuSpojené státy
-
Southwest Oncology GroupNational Cancer Institute (NCI)DokončenoRakovina močového měchýře | Přechodná buněčná rakovina ledvinové pánvičky a močovodu | Rakovina močové trubiceSpojené státy
-
European Organisation for Research and Treatment...DokončenoSarkomFrancie, Belgie, Spojené království, Holandsko